Type
Business expansion
Country
Ireland
Region
Southern and Eastern; South-West (IRL);
Location of affected unit(s)
Cork
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

150 jobs
Number of planned job creations
Job creation
Announcement Date
29 March 2007
Employment effect (start)
Foreseen end date

Description

Pharmaceutical giant GlaxoSmithKline (GSK) is expected to unveil plans today, 29 March 2007, to begin production of a new anti-cancer drug at its Cork plant which will create 150 jobs. GSK obtained approval from the US regulator, the Food and Drug Administration (FDA), for the breast cancer treatment drug Tykerb, and the company is planning to commence production of the drug at the Currabinny site near Carrigaline, where it was researched and developed. GSK already employs 1,400 people in Ireland, including between 600 and 700 people at the Co Cork site. Production of the new drug will involve a multimillion Euro investment which will create some 150 jobs. GSK's plant in Currabinny was established in 1974 and is currently the sole production site for a number of the company's top-selling drugs. The investment will be good news for both Cork and the wider economy following some setbacks and job losses in the pharmaceuticals sector.


Sources

  • 29 March 2007: The Irish Times

Citation

Eurofound (2007), Glaxo Smith Kline, Business expansion in Ireland, factsheet number 65199, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/65199.